Results 241 to 250 of about 14,544 (270)

The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

Nature Reviews Clinical Oncology, 2023
Nicholas Turner
exaly  

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

The adenosine pathway in immuno-oncology

Nature Reviews Clinical Oncology, 2020
Bertrand Allard, Laurence Buisseret, John Stagg   +2 more
exaly  

[Aldose reductase inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 1992
T, Yoneta, E, Tagashira
openaire   +1 more source

[Imidazolidine/thiazolidine-acetate aldose reductase inhibitors].

Annales pharmaceutiques francaises, 2001
We studied a new family of aldose-reductase inhibitors with an imidazolidine arylmethylene and thiazolidine-acetate structure susceptible to prevent ocular, renal and vascular complications of insulin-dependent diabetes mellitus. We examined the role of the enzyme in the pathological processes involved and reviewed knowledge of known aldose reductase ...
openaire   +1 more source

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Aldose reductase inhibitors

2006
openaire   +1 more source

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly